We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
BMC Positions:
Letter Responding to PMPRB Board Chair (June 8, 2021) (français)

Letter to the Prime Minister Regarding PMPRB (May 28, 2021) (français)

Submission to Finance Canada: Priorities for the Federal Budget (February 18, 2021)

Submission to the Standing Committee on Health: PMPRB Guidelines (November 6, 2020) (français)

Letter to the Minister of Health (August 10, 2020) (français)

Submission to the House of Commons Standing Committee on Finance (August 2020)

Submission Regarding PMPRB Revised Draft Guidelines (August 2020) (français)

Letter to the Minister of Health (June 19, 2020) (français)

Submission to the House of Commons Standing Committee on Health (May 2020)

Submission Regarding Draft Guidelines to Implement the Patented Medicines Regulations, as amended (February 2020)

Letter to Health Canada Regarding Proposed Patented Medicines Regulations (February 2018)

Submission Regarding PMPRB Modernization (October 2016)